创新医疗管理股份有限公司 简式权益变动报告书 上市公司名称：创新医疗管理股份有限公司 股票代码：002173 信息披露义务人一：上海洸焕科技有限公司（曾用名：上海瑞鑫融资租赁有限公司） 住所：中国（上海）自由贸易试验区世博村路231号2单元3层328室 通讯地址：上海市浦东新区博霞路11号 信息披露义务人二：上海岩衡投资管理合伙企业（有限合伙） 住所：上海市金山区朱泾镇临源街750号5幢177F 通讯地址：上海市浦东新区环科路1455号模力社区T1 32F 股份变动性质：股份减少（持股比例降至5%以下） 签署日期：2025年4月30日 1 上市地点：深圳证券交易所 股票简称：创新医疗 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》《上市公司收购管理办法》 《公开发行证券的公司信息披露内容与格式准则第 15 号——权益变动报告书》及相关 法律、法规编写本权益变动报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违反信 息披露义务人内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》《公开发行证券的 公司信息披露内容与格式准则第 ...

证券代码：002173 证券简称：创新医疗 公告编号：2025-024 创新医疗管理股份有限公司 关于持股 5%以上股东减持至 5%以下的权益变动提示性公告 持股 5%以上股东上海洸焕科技有限公司（曾用名：上海瑞鑫融资租赁有限 公司）及其一致行动人上海岩衡投资管理合伙企业（有限合伙）保证向本公司提 供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、本次权益变动后，上海洸焕科技有限公司（以下简称"上海洸焕"）持 有创新医疗管理股份有限公司（以下简称"公司"）股份22,064,122股，占公司 总股本的4.99998%，不再是公司持股5%以上股东。 2、本次上海洸焕及其一致行动人上海岩衡投资管理合伙企业（有限合伙） （以下简称"岩衡投资"）权益变动，系因公司回购注销业绩补偿股份及注销已 回购股份事项致其持股比例发生变动，及其因自身资金安排需要减持公司股份所 致。该权益变动不会导致公司控股股东、实际控制人发生变化，不会影响公司的 治理结构和持续经营。 公司于近日收到上海洸焕《简式权益变动报告书》等，获悉上海洸焕于2 ...

序号股票简称PE(TTM)PE(静)市净率总市值(元)8创新医疗-40.51-45.232.4142.50亿行业平均 38.6644.753.42152.65亿行业中值38.3646.642.7251.49亿1润达医疗-313.36207.372.70114.63亿2何氏眼 科-135.21-117.661.6932.24亿3*ST生物-102.63-99.788.4319.80亿4普瑞眼科-71.97-64.663.0965.86亿5诚达 药业-67.32-115.331.5132.41亿6皓宸医疗-48.55-58.395.7622.01亿7国际医学-45.20-45.453.24115.51亿9金域 医学-36.51-37.392.07142.54亿10百诚医药-29.56-72.171.4938.07亿11迪安诊断-22.95-25.781.4192.12亿 5月6日，创新医疗今日收盘9.63元，上涨5.13%，最新市净率2.41，创22天以来新低，总市值42.50亿 元。 股东方面，截至2025年3月31日，创新医疗股东户数68155户，较上次增加8902户，户均持股市值35.28 万元，户均持股数 ...

Group 1 - The core viewpoint of the news is that Innovation Medical's stock has shown a slight increase, but the company is facing significant challenges in its financial performance, with declining revenue and increasing losses [1] - As of April 29, Innovation Medical's closing price was 8.96 yuan, up 2.75%, with a latest price-to-book ratio of 2.24 and a total market capitalization of 3.954 billion yuan [1] - On April 29, the net inflow of main funds into Innovation Medical was 23.82 million yuan, but over the past five days, there was a total outflow of 22.19 million yuan [1] Group 2 - For the first quarter of 2025, Innovation Medical reported operating revenue of 193 million yuan, a year-on-year decrease of 3.98%, and a net loss of approximately 13.94 million yuan, a year-on-year increase in losses of 368.03%, with a gross profit margin of 8.96% [1] - The company has a TTM PE ratio of -37.69 and a static PE ratio of -42.08, indicating significant financial distress compared to the industry average PE ratios of 37.55 and 42.71 respectively [2] - The industry average market capitalization is 14.953 billion yuan, while Innovation Medical's market capitalization is significantly lower at 3.954 billion yuan [2]

Policy Developments - The National Medical Products Administration (NMPA) released the "Quality Management Specifications for Online Sales of Medical Devices," effective from October 1, 2025, which emphasizes qualification review, information transparency, and risk prevention for online medical device sales [1] Drug and Device Approvals - Insilico Medicine's INS018_055 tablet is expected to receive breakthrough therapy designation for treating idiopathic pulmonary fibrosis [2] - Yuyuan Pharmaceutical's injectable Ganciclovir has passed the consistency evaluation for generic drugs, which will enhance the company's market share and competitiveness [3] - Warner Pharmaceuticals' Bismuth Potassium Citrate Granules have also passed the consistency evaluation for generic drugs, benefiting future market sales [4] - Changchun High-tech's subsidiary, Jinsai Pharmaceutical, received approval for clinical trials of Fuxin Qibai monoclonal antibody injection, aimed at treating endometriosis [5] Financial Reports - Yunnan Baiyao reported a Q1 2025 net profit of 1.935 billion yuan, a 13.67% increase year-on-year, with total revenue of 10.841 billion yuan, up 0.62% [6] - WuXi AppTec's Q1 2025 net profit surged by 89.06% to 3.672 billion yuan, driven by revenue growth and operational efficiency improvements [7][8] - Kefu Medical's 2024 annual report showed a net profit increase of 22.6% to 312 million yuan, with revenue of 2.983 billion yuan, up 4.53% [9] - Hongbo Pharmaceutical's Q1 2025 net profit increased by 226.47% to 11.974 million yuan, with revenue of 16.9 million yuan, up 29.61% [10] Capital Market Activities - Jiangsu Hengrui Medicine has received approval from the China Securities Regulatory Commission for its Hong Kong IPO, planning to issue up to 815.1 million shares [11] - Merck announced its acquisition of SpringWorks for approximately $3.9 billion in equity value [12] - China Merchants Bio intends to increase its stake in Renfu Pharmaceutical by 0.5%-1% within six months, reflecting confidence in the company's future [13] Industry Developments - Xiangyu Medical expects to obtain registration certificates for seven robotic products by 2025, focusing on rehabilitation and other medical applications [14] - Soundon Medical has formed a strategic partnership with MED-EL's BHM to advance global bone conduction hearing solutions [16] - Hanyu Pharmaceutical signed a comprehensive cooperation agreement with Huawei Cloud to focus on "AI Smart Drugs" in drug development [17] Public Sentiment Alerts - Innovative Medical announced that shareholder Shanghai Guanghuan Technology reduced its stake by 3.41 million shares, representing 0.8191% of the total circulating shares [18]

证券代码：002173 证券简称：创新医疗 公告编号：2025-023 创新医疗管理股份有限公司 关于持股 5%以上股东权益变动触及 1%的提示性公告 股东上海洸焕科技有限公司保证向本公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 创新医疗管理股份有限公司 创新医疗管理股份有限公司（以下简称"公司"）于2025年3月24日在《证 券时报》、《证券日报》、《上海证券报》、《中国证券报》和巨潮资讯网 （www.cninfo.com.cn）上披露了《关于持股5%以上股东、董事、高管减持股份 的预披露公告》（公告编号：2025-010），上海洸焕科技有限公司（以下简称"上 海洸焕"）计划以集中竞价交易、大宗交易方式减持本公司股份，减持数量不超 过13,238,487股，即不超过公司总股本的3%。 公司近日收到上海洸焕《股份减持计划实施触及变动1%的告知函》，自2025 年4月21日至2025年4月25日期间，上海洸焕权益变动触及公司总股本的1%。现将 具体情况公告如下： | 1．基本情况 | | | | | --- | ...

Core Viewpoint - The company, Innovation Medical, has released its first quarter report for 2025, which has not been audited, and emphasizes the accuracy and completeness of the financial information provided [3][6]. Financial Data Summary - The company confirms that there are no adjustments or restatements required for previous accounting data [3]. - There are no non-recurring profit and loss items applicable for the quarter [3]. - The company has not defined any non-recurring profit and loss items as recurring [3]. Shareholder Information - The report includes details about the total number of common shareholders and the top ten shareholders, but specific data is not provided in the document [5]. - The company has not engaged in any share lending activities related to the top ten shareholders [5]. Other Important Matters - The first quarter report has not undergone an audit, indicating that the financial statements are preliminary and subject to change [6].

Financial Performance - The company reported a basic earnings per share of -0.0300 yuan for Q1 2025, a decrease of 347.76% compared to -0.0067 yuan in Q1 2024 [1] - Net profit for Q1 2025 was -0.14 billion yuan, representing a significant decline of 366.67% from -0.03 billion yuan in Q1 2024 [1] - Operating revenue decreased by 3.98% to 1.93 billion yuan in Q1 2025, down from 2.01 billion yuan in Q1 2024 [1] - The return on equity was -0.79% in Q1 2025, a drop of 393.75% from -0.16% in Q1 2024 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 15,020.82 million shares, accounting for 36.07% of the circulating shares, with a decrease of 302.26 million shares compared to the previous period [2] - The largest shareholder, Chen Xiaying, holds 7,761.70 million shares, representing 18.64% of the total share capital, with no change [3] - Shanghai Guanghuan Technology Co., Ltd. holds 3,372.02 million shares (8.10%), unchanged from the previous period [3] - Hangzhou Changjian Investment Partnership (Limited Partnership) decreased its holdings by 392.00 million shares to 1,814.42 million shares (4.36%) [3] Dividend Policy - The company has decided not to distribute dividends or transfer shares in this period [3]

Revenue and Profitability - The company's revenue for Q1 2025 was ¥193,334,481.58, a decrease of 3.98% compared to ¥201,344,535.99 in the same period last year[4] - The net profit attributable to shareholders was -¥13,937,418.26, representing a decline of 368.03% from -¥2,977,863.39 year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥14,970,488.85, a decrease of 452.67% compared to -¥2,708,735.09 in the previous year[4] - Basic and diluted earnings per share were both -¥0.03, down 347.76% from -¥0.0067 in the previous year[4] - Net profit for the current period was a loss of CNY 13,890,668.31, compared to a loss of CNY 2,979,559.99 in the previous period[15] - The net profit attributable to the parent company was -13,937,418.26, compared to -2,977,863.39 in the previous period, indicating a significant increase in losses[16] - The total comprehensive income attributable to the parent company was -13,937,418.26, compared to -2,977,863.39 in the previous period, reflecting a worsening financial position[16] - The basic and diluted earnings per share were both -0.03, compared to -0.0067 in the previous period, showing a decline in profitability[16] Cash Flow and Liquidity - The net cash flow from operating activities improved to ¥4,741,047.29, a significant increase of 126.84% from -¥17,663,752.00 in the same period last year[4] - Cash inflows from operating activities totaled 191,773,031.89, up from 182,904,706.98 in the previous period, indicating improved cash generation[17] - The net cash flow from operating activities was 4,741,047.29, a recovery from -17,663,752.00 in the previous period, suggesting operational improvements[18] - Cash inflows from investing activities were 55,025,416.74, down from 304,959,178.42 in the previous period, indicating reduced investment activity[18] - The net cash flow from investing activities was 21,058,502.54, a significant decrease from 288,142,403.29 in the previous period, reflecting a shift in investment strategy[18] - The net cash flow from financing activities was 486,724.90, down from 10,452,995.48 in the previous period, indicating a reduction in financing activities[18] - The ending cash and cash equivalents balance was 143,789,708.17, down from 529,951,281.78 in the previous period, showing a decrease in liquidity[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,164,041,606.40, a decrease of 1.81% from ¥2,203,947,708.41 at the end of the previous year[4] - Total operating costs increased to CNY 205,240,260.34, up 1.0% from CNY 202,244,492.52[15] - Total assets decreased to CNY 2,164,041,606.40 from CNY 2,203,947,708.41, reflecting a decline of 1.8%[14] - Total liabilities decreased to CNY 400,833,433.03 from CNY 426,848,866.73, a reduction of 6.1%[13] - Current assets totaled CNY 566,946,305.73, down 5.3% from CNY 598,852,540.99[12] - Non-current assets totaled CNY 1,597,095,300.67, a slight decrease from CNY 1,605,095,167.42[13] - The company's retained earnings showed a deficit of CNY 1,412,129,160.15, worsening from a deficit of CNY 1,398,191,741.89[13] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 68,155[9] Non-Recurring Items - The company reported a non-recurring gain of ¥1,033,070.59, primarily from fair value changes of financial assets and liabilities[5] - The decline in net profit was attributed to changes in payment methods for rehabilitation diseases and dynamic adjustments in medical insurance payment standards[7] Audit Status - The first quarter report was not audited, which may affect the reliability of the financial data presented[19]

Core Insights - Innovation Medical Management Co., Ltd. reported a decline in operating performance for 2024 due to adjustments in medical insurance settlement policies, despite an increase in outpatient and inpatient volumes [1] - The company is focusing on enhancing supply chain management and developing self-funded medical projects to ensure stable operations [1] - Innovation Medical is investing in cutting-edge fields such as brain-computer interfaces and AI medical models, which have garnered significant attention from the capital market [1] Group 1: AI Medical Applications - In August 2024, Innovation Medical announced a strategic investment in Hangzhou Quanzhen Medical Technology Co., Ltd., acquiring a 20.5532% stake, recognizing the potential of AI in healthcare [2] - The AI medical model developed by Quanzhen Medical includes features like pre-consultation and electronic medical record writing, which enhance doctors' efficiency and diagnostic quality [2][3] - The AI model is expected to generate revenue of 4.4 million yuan in 2024, with a target of 40 million yuan in 2025, indicating strong growth potential [3] Group 2: Brain-Computer Interface Developments - Innovation Medical's investment in Bole Brain-Computer Technology Co., Ltd. has led to the development of a B-end product for rehabilitation training, currently undergoing clinical trials [4] - The C-end product, designed for enhancing upper limb function in stroke patients, is in mass production and expected to launch in 2025, marking a significant innovation in the market [4][5] - The C-end product aims to improve the quality of life for stroke patients, potentially saving them significant annual costs in care and hospital expenses [5]